Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1 NCT04322682- A total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio,… Continue reading "(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization"
Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study https://doi.org/10.1007/s00705-021-04956-9 NCT04351295-This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the… Continue reading "(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation"
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial https://doi.org/10.1016/S2213-2600(20)30556-7 NCT04341584-The study was stopped early following the recommendation of the data and safety monitoring board, after the recruitment of… Continue reading "(26 Jan 2021) Anakinra- did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia"
Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial https://doi.org/10.1159/000512063 NCT04273321- this trial was terminated early because the number of patients with COVID-19 pneumonia in all the… Continue reading "(25 Jan 2021) Corticosteroids- short-term early use may prolong SARS-CoV 2 shedding"
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial https://doi.org/10.1001/jama.2021.0202 NCT04427501- Among the 577 patients who were randomized and received an infusion (mean age, 44.7… Continue reading "(22 Jan 2021) Bamlanivimab-associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11"
Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial https://doi.org/10.4103/ijmr.IJMR_3665_20 CTRI/2020/04/024729-his randomized clinical trial was done with a sample size of 60. Nasal CQN was associated with local irritation in seven and non-compliance in one of… Continue reading "(22 Jan 2021) Chloroquine- No significant differences in clinical or virological outcome with nasal drops"
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial https://doi.org/10.1001/jama.2021.0202 NCT04403685-A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed… Continue reading "(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days"
Efficacy of canakinumab in mild or severe COVID-19 pneumonia https://doi.org/10.1002/iid3.400 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19) were enrolled: 17 patients treated with standard therapy and 17 patients treated with a subcutaneous… Continue reading "(20 Jan 2021) Canakinumab- causes rapid and long-lasting improvement in oxygenation levels"
Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019 https://doi.org/10.1002/jmv.26798 For all patients, there were no significant differences in the change of body temperature, the time for negative conversion and hospital… Continue reading "(16 Jan 2021) Lopinavir/Ritonavir (LPV/r), Arbidol (ARB) and Methylprednisolone -LPV/r combined with ARB no effect,"
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study https://doi.org/10.1186/s12879-021-05773-w Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were… Continue reading "(16 Jan 2021) Hydroxychloroquine- associated with a decreased rate of subsequent hospitalization"
